Sp982
SCOPE OF THE PROBLEM: DISEASE DEFINITION AND EPIDEMIOLOGY
Date
May 8, 2023
Explore related products in the following collection:
Tracks
Related Products
ESOPHAGUS
This session will have six talks on the indications, limitations, procedural and technical aspects on clinically useful GI physiology tests. The attendees will learn for which patients these test can be of value, and what type of results you can expect and how reliable these are…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTERIM RESULTS FROM A FIRST-IN-HUMAN STUDY OF THE ANTI-IL-15 ANTIBODY CALY-002 FOR TREATING CELIAC DISEASE AND EOSINOPHILIC ESOPHAGITIS
INTRODUCTION Interleukin-15 (IL-15) is an important cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses…